Avandia and Actos Add Strengthened “Black Box” Warnings On Heart Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling update includes contraindication for patients with NYHA Class III or IV heart failure.
You may also be interested in...
Avandia Expands Black Box With Heart Attack Risk Information
FDA revises labeling for all oral anti-diabetics to include warning about the absence of conclusive evidence of cardiovascular risk.
Avandia Expands Black Box With Heart Attack Risk Information
FDA revises labeling for all oral anti-diabetics to include warning about the absence of conclusive evidence of cardiovascular risk.
Avandia Monotherapy Use Curtailed in Canada
Cardiac safety concerns fuel Health Canada to recommend rosiglitazone as second-line treatment for diabetes.